Megan Lerner to Biomarkers, Tumor
This is a "connection" page, showing publications Megan Lerner has written about Biomarkers, Tumor.
Connection Strength
0.689
-
Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Invest. 2017 Oct 21; 35(9):573-585.
Score: 0.117
-
Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Cancer Lett. 2015 Apr 10; 359(2):314-24.
Score: 0.097
-
Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling. Cancer Invest. 2014 May; 32(4):136-43.
Score: 0.091
-
Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas. 2012 Apr; 41(3):474-80.
Score: 0.080
-
Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest. 2012 Feb; 30(2):189-97.
Score: 0.078
-
In vivo characterization of several rodent glioma models by 1H MRS. NMR Biomed. 2012 Apr; 25(4):685-94.
Score: 0.077
-
Biomarker identification in human pancreatic cancer sera. Pancreas. 2008 Jan; 36(1):61-9.
Score: 0.060
-
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005 Dec; 124(6):838-45.
Score: 0.052
-
Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer. 2011 Nov; 74(2):206-11.
Score: 0.019
-
DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011 Mar 15; 71(6):2328-38.
Score: 0.018